Immunologic Biomarkers for Clinical and Therapeutic Management of Psoriasis
Figure 6
Lymphocyte proliferation toward Candida albicans and CEF antigens as performed at baseline (T0) and after 24 weeks of treatment (T2) in a representative group of 30 patients under therapy with etanercept (10), adalimumab (10), or infliximab (10). Stimulation indexes of CD4+ (a) and CD8+ (b) lymphocytes.